---
document_datetime: 2023-09-21 18:00:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zaltrap-epar-all-authorised-presentations_en.pdf
document_name: zaltrap-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0375566
conversion_datetime: 2025-12-28 12:37:09.484469
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)   | Strength   | Pharmaceutical Form                   | Route of        | Packaging    | Content      | Pack size   |
|------------------|--------------|------------|---------------------------------------|-----------------|--------------|--------------|-------------|
| EU/1/12/814/001  | Zaltrap      | 25 mg/ml   | Concentrate for solution for infusion | Intravenous use | vial (glass) | 100 mg/4 ml  | 1 vial      |
| EU/1/12/814/002  | Zaltrap      | 25 mg/ml   | Concentrate for solution for infusion | Intravenous use | vial (glass) | 100 mg/4 ml  | 3 vials     |
| EU/1/12/814/003  | Zaltrap      | 25 mg/ml   | Concentrate for solution for infusion | Intravenous use | vial (glass) | 200 mg/ 8 ml | 1 vial      |